Skip to main content
SpringerLink
Log in

Analysis of Expression of Genes CLN3, GABBR1, and WFS1 in Patients with Parkinson’s Disease

  • EXPERIMENTAL WORKS
  • Published:
Molecular Genetics, Microbiology and Virology Aims and scope Submit manuscript

Abstract

Parkinson’s disease (PD) is one of the most common neurodegenerative pathologies. This disorder is associated with death of predominantly dopaminergic neurons. A characteristic feature of PD is a long latent period of disease development, which makes it impossible to investigate and diagnose PD at the earliest clinical stages. One of the approaches to solving this problem is the examination of the peripheral blood of untreated PD patients at the early clinical stages. Changes in relative mRNA levels of genes in peripheral blood can be considered as potential biomarkers at the early stages of PD. In this study, we analyzed changes in relative mRNA levels of genes CLN3, GABBR1, and WFS1 in peripheral blood in treated and untreated PD patients and in comparison groups using RT-qPCR with TaqMan probes. All the known functions of the proteins of the studied genes, as well as the identified associations of these genes with various neurological diseases, may indicate their possible involvement in PD pathogenesis. However, no statistically significant changes in mRNA levels in PD patients relative to the control were shown for any gene. No significant changes in relative mRNA levels in the neurological control group were shown either. So, the data presented in this paper suggest that genes CLN3, GABBR1, and WFS1 do not contribute to the pathogenesis of the disease, at least at the mRNA level, at the early symptomatic stages in patients with PD and, therefore, cannot be considered as biomarkers of the early stages of PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Del Tredici, K. and Braak, H., Review: Sporadic Parkinson’s disease: Development and distribution of alpha-synuclein pathology, Neuropathol. Appl. Neurobiol., 2016, vol. 42, no. 1, pp. 33–50. https://doi.org/10.1111/nan.12298

    Article  CAS  PubMed  Google Scholar 

  2. Lunati, A., Lesage, S., and Brice, A., The genetic landscape of Parkinson’s disease, Rev. Neurol., 2018, vol. 174, no. 9, pp. 628–643. https://doi.org/10.1016/j.neurol.2018.08.004

    Article  CAS  PubMed  Google Scholar 

  3. Borrageiro, G., Haylett, W., Seedat, S., Kuivaniemi, H., and Bardien, S., A review of genome-wide transcriptomics studies in Parkinson’s disease, Eur. J. Neurosci., 2018, vol. 47, no. 1, pp. 1–16. https://doi.org/10.1111/ejn.13760

    Article  PubMed  Google Scholar 

  4. Kalia, L.V. and Lang, A.E., Parkinson’s disease, Lancet, 2015, vol. 386, no. 9996, pp. 896–912. https://doi.org/10.1016/s0140-6736(14)61393-3

    Article  CAS  Google Scholar 

  5. Goetz, C.G., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G.T., Counsell, C., et al., Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations, Mov. Disord., 2004, vol. 19, no. 9, pp. 1020–1028. https://doi.org/10.1002/mds.20213

    Article  PubMed  Google Scholar 

  6. Suslov, O. and Steindler, D.A., PCR inhibition by reverse transcriptase leads to an overestimation of amplification efficiency, Nucleic Acids Res., 2005, vol. 33, no. 20, p. e181. https://doi.org/10.1093/nar/gni176

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Livak, K.J. and Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(–Delta Delta C(T)) Method, Methods, 2001, vol. 25, no. 4, pp. 402–408. https://doi.org/10.1006/meth.2001.1262

    Article  CAS  Google Scholar 

  8. Alieva, A.K., Shadrina, M.I., Filatova, E.V., Karabanov, A.V., Illarioshkin, S.N., Limborska, S.A., et al., Involvement of endocytosis and alternative splicing in the formation of the pathological process in the early stages of Parkinson’s disease, BioMed Res. Int., 2014, vol. 2014, article ID 718732. https://doi.org/10.1155/2014/718732

    Article  PubMed  PubMed Central  Google Scholar 

  9. Shadrina, M., Nikopensius, T., Slominsky, P., Illarioshkin, S., Bagyeva, G., Markova, E., et al., Association study of sporadic Parkinson’s disease genetic risk factors in patients from Russia by APEX technology, Neurosci. Lett., 2006, vol. 405, no. 3, pp. 212–216. https://doi.org/10.1016/j.neulet.2006.06.066

    Article  CAS  PubMed  Google Scholar 

  10. Chandrachud, U., Walker, M.W., Simas, A.M., Heetveld, S., Petcherski, A., Klein, M., et al., Unbiased cell-based screening in a neuronal cell model of batten disease highlights an interaction between Ca2+ homeostasis, autophagy, and CLN3 protein function, J. Biol. Chem., 2015, vol. 290, no. 23, pp. 14 361–14 380. https://doi.org/10.1074/jbc.M114.621706

    Article  CAS  Google Scholar 

  11. Phillips, S.N., Benedict, J.W., Weimer, J.M., Pearce, D.A., et al., CLN3, the protein associated with batten disease: Structure, function and localization, J. Neurosci. Res., 2005, vol. 79, no. 5, pp. 573–583. https://doi.org/10.1002/jnr.20367

    Article  CAS  PubMed  Google Scholar 

  12. Perland, E., Bagchi, S., Klaesson, A., Fredriksson, R., et al., Characteristics of 29 novel atypical solute carriers of major facilitator superfamily type: Evolutionary conservation, predicted structure and neuronal co-expression, Open Biol., 2017, vol. 7, no. 9, pp. 170 142–170 157. https://doi.org/10.1098/rsob.170142

    Article  CAS  Google Scholar 

  13. Tuxworth, R.I., Chen, H., Vivancos, V., Carvajal, N., Huang, X., and Tear, G., The Batten disease gene CLN3 is required for the response to oxidative stress, Hum. Mol. Genet., 2011, vol. 20, no. 10, pp. 2037–2047. https://doi.org/10.1093/hmg/ddr088

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Nuzhnyi, E.P., Yakimovskii, A.F., Timofeeva, A.A., Usenko, T.S., Nikolaev, M.A., Emel’yanov, A.K., et al., Mutation del 1.02 kb in the CLN3 gene and extrapyramidal syndrome, Zh. Nevrol. Psikhiatr. im. S. S. Korsakova, 2016, vol. 116, no. 8, pp. 50–53. https://doi.org/10.17116/jnevro20161168150-53

    Article  CAS  PubMed  Google Scholar 

  15. Chalifoux, J.R. and Carter, A.G., GABAB receptors modulate NMDA receptor calcium signals in dendritic spines, Neuron, 2010, vol. 66, no. 1, pp. 101–113. https://doi.org/10.1016/j.neuron.2010.03.012

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Chalifoux, J.R. and Carter, A.G., GABAB receptor modulation of synaptic function, Curr. Opin. Neurobiol., 2011, vol. 21, no. 2, pp. 339–344. https://doi.org/10.1016/j.conb.2011.02.004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Galvan, A., Eftekhari, S., Cloarec, R., Gouty-Colomer, L.A., Dufour, A., and Riffault, B., Localization and pharmacological modulation of GABA-B receptors in the globus pallidus of parkinsonian monkeys, Exp. Neurol., 2011, vol. 229, no. 2, pp. 429–439. https://doi.org/10.1016/j.expneurol.2011.03.010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Lozovaya, N., Eftekhari, S., Cloarec, R., Gouty-Colomer, L.A., Dufour, A., Riffault, B., et al., GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease, Nat. Commun., 2018, vol. 9, no. 1, p. 1422. https://doi.org/10.1038/s41467-018-03802-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Wang, Q., Li, W.X., Dai, S.X., Guo, Y.C., Han, F.F., Zheng, J.J., et al., Meta-analysis of Parkinson’s disease and Alzheimer’s disease revealed commonly impaired pathways and dysregulation of NRF2-dependent genes, J. Alzheimer’s Dis., 2017, vol. 56, no. 4, pp. 1525–1539. https://doi.org/10.3233/jad-161032

    Article  CAS  Google Scholar 

  20. Takeda, K., Inoue, H., Tanizawa, Y., Matsuzaki, Y., Oba, J., Watanabe, Y., et al., WFS1 (Wolfram syndrome 1) gene product: Predominant subcellular localization to endoplasmic reticulum in cultured cells and neuronal expression in rat brain, Hum. Mol. Genet., 2001, vol. 10, no. 5, pp. 477–484. https://doi.org/10.1093/hmg/10.5.477

    Article  CAS  PubMed  Google Scholar 

  21. Takei, D., Ishihara, H., Yamaguchi, S., Yamada, T., Tamura, A., Katagiri, H., et al., WFS1 protein modulates the free Ca2+ concentration in the endoplasmic reticulum, FEBS Lett., 2006, vol. 580, no. 24, pp. 5635–5640. https://doi.org/10.1016/j.febslet.2006.09.007

    Article  CAS  PubMed  Google Scholar 

  22. Osman, A.A., Saito, M., Makepeace, C., Permutt, M.A., Schlesinger, P., and Mueckler, M., Wolframin expression induces novel ion channel activity in endoplasmic reticulum membranes and increases intracellular calcium, J. Biol. Chem., 2003, vol. 278, no. 52, pp. 52 755–52 762. https://doi.org/10.1074/jbc.M310331200

    Article  CAS  Google Scholar 

  23. Fonseca, S.G., Fukuma, M., Lipson, K.L., Nguyen, L.X., Allen, J.R., Oka, Y., et al., WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic beta-cells, J. Biol. Chem., 2005, vol. 280, no. 47, pp. 39 609–39 615. https://doi.org/10.1074/jbc.M507426200

    Article  CAS  Google Scholar 

  24. Sakakibara, Y., Sekiya, M., Fujisaki, N., Quan, X., and Iijima, K.M., Knockdown of wfs1, a fly homolog of Wolfram syndrome 1, in the nervous system increases susceptibility to age- and stress-induced neuronal dysfunction and degeneration in Drosophila, PLoS Genet., 2018, vol. 14, no. 1, p. e1 007 196. https://doi.org/10.1371/journal.pgen.1007196

    Article  CAS  Google Scholar 

  25. Shadrina, M., Filatova, E., Alieva, A., Stavrovskaya, A., Khudoerkov, R., Limborska, S., et al., Transcriptome profiling of 6-OHDA model of Parkinson’s disease, Adv. Biosci. Biotechnol., 2013, vol. 4, pp. 28–35. https://doi.org/10.4236/abb.2013.46A005

    Article  CAS  Google Scholar 

Download references

Funding

This work was supported by the Russian Science Foundation, no. 17-75-10119. The work was carried out using the instruments of the Center for Genetic and Cellular Technologies Center for Collective Use of the Institute of Molecular Genetics of the Russian Academy of Sciences.

Author information

Authors and Affiliations

  1. Institute of Molecular Genetics, Russian Academy of Sciences, 125367, Moscow, Russia

    Yu. S. Starovatykh, M. M. Rudenok, P. A. Slominsky, M. I. Shadrina & A. Kh. Alieva

  2. Research Center of Neurology, 125367, Moscow, Russia

    A. V. Karabanov & S. N. Illarioshkin

Authors
  1. Yu. S. Starovatykh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. M. Rudenok
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. V. Karabanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. N. Illarioshkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. A. Slominsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. I. Shadrina
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Kh. Alieva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yu. S. Starovatykh.

Ethics declarations

COMPLIANCE WITH ETHICAL STANDARDS

Conflict of interest. The authors declare that they have no conflict of interest.

Statement of compliance with standards of research involving humans as subjects. All blood samples were taken with the informed consent of the subjects. The study was approved by the Ethics Committee of the Scientific Center of Neurology of the Russian Academy of Sciences.

ADDITIONAL INFORMATION

Starovatykh Yu.S.—e-mail: iggdrasil247@gmail.com; https://orcid.org/0000-0001-6646-886X

Rudenok M.M.—e-mail: margaritamrudenok@gmail.com; https://orcid.org/0000-0003-4739-5460

Karabanov A.V.—e-mail: doctor.karabanov@mail.ru; https://orcid.org/0000-0003-0795-9743

Illarioshkin S.N.—e-mail: snillario@gmail.com; https://orcid.org/0000-0002-2704-6282

Slominsky P.A.—e-mail: slomin@img.ras.ru; https://orcid.org/0000-0002-4112-2368

Shadrina M.I.—e-mail: shadrina@img.ras.ru; https://orcid.org/0000-0002-9977-043X

Alieva A.Kh.—e-mail: anelja.a@gmail.com; https://orcid.org/0000-0002-6200-4491

Additional information

Translated by K. Lazarev

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Starovatykh, Y.S., Rudenok, M.M., Karabanov, A.V. et al. Analysis of Expression of Genes CLN3, GABBR1, and WFS1 in Patients with Parkinson’s Disease. Mol. Genet. Microbiol. Virol. 35, 85–89 (2020). https://doi.org/10.3103/S089141682002010X

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3103/S089141682002010X

Keywords:

Search

Navigation